Immuneering and Lilly Partner to Evaluate Atebimetinib and Olomorasib in Phase 2 NSCLC Trial

Analysis reveals significant industry trends and economic implications

Release Date

2025-08-25

Category

Clinical Trial Event

Reference

Source

Breakthrough Clinical Results

Immuneering Corporation announced a clinical supply agreement with Eli Lilly and Company for olomorasib, to be used in combination with Immuneering's atebimetinib in a Phase 2 clinical trial. The trial will focus on patients with locally advanced or metastatic KRAS G12c-mutant non-small cell lung cancer (NSCLC) who have progressed on prior therapy. The combination aims to provide a vertical blockade of the RAS-MAPK pathway, potentially improving outcomes in this patient population with limited treatment options. Immuneering retains global development and commercialization rights to atebimetinib.

Key Highlights

  • Clinical supply agreement between Immuneering and Eli Lilly for olomorasib.
  • Phase 2 trial planned to evaluate atebimetinib in combination with olomorasib in KRAS G12c-mutant NSCLC.
  • Combination therapy aims to block the RAS-MAPK pathway.
  • Immuneering retains global rights to atebimetinib.

Drug used in other indications

Clinical Indications and Intervention Models for Atebimetinib and Olomorasib Beyond NSCLC

Based on the available information, I cannot provide specific details about clinical indications beyond non-small cell lung cancer (NSCLC) for atebimetinib and olomorasib, or their intervention models in clinical trials.

To properly address this query, information would be needed about:

  • Additional cancer types or other diseases where these compounds are being investigated
  • Clinical trial designs for these alternative indications
  • Dosing regimens and administration protocols
  • Combination therapies being tested with these agents
  • Phase information for the various trials
  • Patient populations being targeted
  • Primary and secondary endpoints of these studies
  • Intervention methodologies specific to each indication

Without this specific information in the provided context, I cannot detail the other indications for which atebimetinib and olomorasib are being trialed beyond NSCLC, nor can I describe the intervention models employed in these trials.

For accurate and current information on clinical trials involving these compounds, consulting clinical trial registries such as ClinicalTrials.gov or the pharmaceutical companies developing these agents would be recommended.

Incidence and Prevalence

Global Incidence and Prevalence of Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer with a world-wide annual incidence of around 1.3 million. It accounts for over 85% of all lung cancers according to 2022 data, making it a significant global health concern.

Lung cancer as a whole is the second most common cancer in the world and the leading cause of cancer deaths globally. It kills 1.8 million people each year, underscoring its substantial impact on public health. Despite advances in treatment options including targeted therapy, the overall survival rate of lung cancer remains low.

Regional epidemiological data shows varying patterns. In Shenzhen, China, the average crude incidence rate of lung cancer was 27.1 per 100,000 from 2008 to 2018, with an annual percentage change of 2.7%. Notably, lung cancer is the most commonly diagnosed cancer in China since the late twentieth century.

Age-specific trends reveal important patterns. The global age-standardized incidence rate (ASIR) of early-onset lung cancer (EOLC) decreased from 4.81 per 100,000 in 1990 to 3.13 in 2021, with a steeper decline in males (AAPC: -1.79) compared to females (AAPC: -0.63). Middle-onset lung cancer (MOLC) incidence also declined from 92.77 to 72.47 per 100,000 (AAPC: -0.81), while late-onset lung cancer (LOLC) demonstrated a slight increase from 195.39 to 225.8 per 100,000 (AAPC: 0.43).

Histologically, adenocarcinoma is the largest histological type of lung cancer (69.1% in the Shenzhen study), with an increasing trend observed in females (average annual percentage change of 14.7%). Lung adenocarcinoma is specifically noted as the most common type of lung cancer.

Gender differences are significant. In the UK and the US, the survival rates of women with lung cancer were higher than those of men. Additionally, late-onset lung cancer (LOLC) in females showed a consistent rise in incidence rate (AAPC: 1.13). Projections indicate that although lung cancer would generally decline in the next decade, the incidence, mortality, and DALY rates of late-onset lung cancer in females might remarkably increase.

Regional variations are notable. East Asia showed the steepest increase in ASIR of late-onset lung cancer (from 229.26 in 1990 to 375.90 in 2021, AAPC = 1.6). According to socio-demographic index (SDI) quintiles, the middle SDI region demonstrated the largest rise in ASIR of late-onset lung cancer.

Age is a significant factor, with elderly patients now representing a bigger proportion of patients with NSCLC, with typical age of onset around 60 years. Young patients are rarely diagnosed with lung cancer, with less than 3.5% of patients presenting with this tumor at an age less than 45.

Despite advances in treatment, the majority of patients are diagnosed with advanced disease and survival remains poor, though there have been relevant advances through the identification of biomarkers.

MoA used in other indications

Clinical Indications and Intervention Models for Atebimetinib and Olomorasib Beyond NSCLC

Based on the available information, I cannot provide specific details about clinical indications beyond non-small cell lung cancer (NSCLC) for atebimetinib (MEK1/2 inhibitor) and olomorasib (PARP7 inhibitor), nor can I describe the intervention models used in these trials.

The context provided does not contain information about:

  • Additional indications being investigated for these compounds beyond NSCLC
  • Intervention models employed in clinical trials for these drugs
  • Clinical trial phases for non-NSCLC indications
  • Study designs or randomization protocols for these investigations

To provide an accurate answer about the additional indications and intervention models for atebimetinib and olomorasib trials, more specific information would be needed from clinical trial databases, scientific publications, or pharmaceutical company pipelines.

For comprehensive information about ongoing clinical trials investigating these compounds, resources such as ClinicalTrials.gov, EU Clinical Trials Register, or direct information from the developing pharmaceutical companies would be valuable sources.